AzTrials
AzTrials

HealthyPhase 3NCT02230397

Efficacy and Tolerance Evaluation of a Topical "Revitalizing" Face Day Cream

A Phase 3 study testing plantaricin a (active product) in people with Healthy, run by Derming SRL at 1 site in Italy.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Aim of the study was to evaluate clinically and by non-invasive instrumental evaluations the "revitalizing" activity of a face cream applied twice a day, morning and evening, for an uninterrupted period of 8 weeks, by healthy female volunteers aged 45-55 years with face ritidosis and women aged 55-65 years not… Read more about this study

Who is it for?
Ages 45 to 65 years, women onlyHealthy volunteers can take part
Conditions the study is for
Healthy
What is being tested?
plantaricin a (active product)
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
33 participants
Where
1 siteItaly
Study dates
Oct 2013to Dec 2013
Phase
Phase 3
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 45 to 65 years
  • Women only
  • Healthy volunteers accepted
  • Adult, Older adult

Who may be able to join

  • female healthy subjects
  • age 45-55 years
  • women aged 55-65 years who are not habitual user of antiage-creams
  • presence of moderate face ritidosis
  • agreeing to present at each study visit without make-up
  • accepting to not change their habits regarding food, physical activity, face cleansing and make- up use
  • accepting not to expose their face to strong UV irradiation (UV session, or sun bathes) during the entire duration of the study
  • accepting to sign the Informed consent form

Who cannot join

  • pregnancy
  • lactation
  • change in the normal habits regarding foods, physical activity, face cleansing and make-up use during the month preceding the test
  • sensitivity to the test products or theirs ingredients
  • subjects whose insufficient adhesion to the study protocol is foreseeable
  • participation in a similar study actually or during the previous 3 months
Show all 22Show fewer
  • change in the normal life habits during the month preceding the inclusion
  • dermatological disease (dermatitis; presence of cutaneous disease on the tested area, as lesions, scars, malformations; recurrent facial/labial herpes)
  • clinical and significant skin condition on the test area (e.g. active eczema, dermatitis, psoriasis etc.)
  • diabetes
  • endocrine disease
  • hepatic disorder
  • renal disorder
  • cardiac disorder
  • pulmonary disease
  • cancer
  • neurological or psychological disease
  • inflammatory/immunosuppressive disease
  • drug allergy
  • drugs/cutaneous medical or surgical procedures at level of the tested area during the previous 3 months
  • anti-inflammatory drugs, anti-histaminic, topic and systemic corticosteroids, narcotic, antidepressant, immunosuppressive drugs (with except of contraceptive or hormonal treatment starting from at least 1 year);
  • assumption of drugs able to influence the test results in the investigator opinion

Trial locations and contacts

1 site in 1 country.

Italy1 site
  • DermIng SRL

    Monza, Monza, 20900

Other trials in Italy

About this study

Official title: Efficacy and Tolerance Evaluation of a Topical "Revitalizing" Face Day Cream: Comparison Within Subjects Versus Placebo

Aim of the study was to evaluate clinically and by non-invasive instrumental evaluations the "revitalizing" activity of a face cream applied twice a day, morning and evening, for an uninterrupted period of 8 weeks, by healthy female volunteers aged 45-55 years with face ritidosis and women aged 55-65 years not habitual user of antiage-creams.

The study foresaw the comparison within subjects of the study product versus placebo (half face method).

It was also aim of this study to evaluate products efficacy and cosmetic acceptability by the volunteers and tolerance both by investigator and volunteers.

Conditions
Healthy
Being tested
plantaricin a (active product), placebo product
Keywords
skin aging, anti-aging cream, wrinkles

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • plantaricin a (active product)Other

    Product application: 8 weeks (one on the right and one on the left face side randomly) twice a day, in the morning and in the evening, with a mild massage

  • placebo productOther

    Product application: 8 weeks (one on the right and one on the left face side randomly) twice a day, in the morning and in the evening, with a mild massage

Study groups in NCT02230397
Study groupRoleWhat they receive
plantaricin a (active product)OtherVolunteers applied the active product for an uninterrupted period of 8 weeks (on the right or on the left face side randomly) twice a day, in the morning and in the evening, with a mild massage.
Receives: Other: plantaricin a (active product)
placebo productOtherVolunteers applied the placebo product for an uninterrupted period of 8 weeks (on the right or on the left face side randomly) twice a day, in the morning and in the evening, with a mild massage
Receives: Other: placebo product

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Profilometry: change from baseline (T4 and T8 vs. T0)

    A picture of crow's feet area was taken thanks to Primos compact portable device (GFMesstechnik); a software able to elaborate 3D representations of skin wrinkles as well as to measure skin principal profilometric parameters in vivo or on skin replicas, according to the law DIN EN ISO 4228; moreover the software compares directly the different images obtained at the times foresee by the protocol (T0, T4 and T8).The portable probe assures a constant distance from the skin as well as a fixed illumination angle of incidence; in this way is possible to acquire standardized and reproducible images.

    Measured: T0 (basal conditions), T4 and T8 (after 4 and 8 week-treatment)

Secondary outcomes (7)
  1. Skin electrical capacitance: change from baseline (T4 and T8 vs. T0)

    Hydration is measured by the instrument Corneometer CM825 (Courage - Khazaka, Köln, Germany): a square sensor (49mm2) frontally covered by a special glass, mounted on a spring cursor able to measure electrical capacity. Leaning the sensor on the skin surface, with a constant pressure thanks to the spring cursor it is possible to perform measures. The sensor acts as a capacitor. When a voltage is applied to this capacitor, the quantity of electric charge stored will be dependent on the dielectric properties of the material in contact with the probe. Water has an unusually high dielectric constant and so its presence in the skin is readily detectable by this method. So the measure of the skin capacitance properties is an indirect expression of its hydration level. To reduce the variability of measurement methods, for each evaluated side, three measures on the same skin area were executed: the adjusted mean will be considered as the real measure value.

    Measured: T0 (basal condition), T4 and T8 (after 4 and 8 week-treatment)

  2. Skin plastoelasticity: change from baseline (T4 and T8 vs. T0)

    Skin plastoelasticity is measured with the instrument Dermal Torque Meter (Dia-Stron Ltd., UK). This instrument is based on the principle of the torsion given to the skin surface by a probe made of two circles that adhere to the skin through shaped adhesive tapes. The internal circle rotation, while the external circle is still, exerts a constant torsion of the skin (torsion time = 1 second with a torque = 9mN*m). The instrument measures the torsion angle (θ) during the mechanical stimulus ("torque on") and after it has ceased ("torque off").For each of the considered curves the cutaneous rotational ratio relative to defined measured times can be measured, obtaining the parameters listed below:

    Ue: immediate extensibility ("torque on" at 0.02 sec.) Uf: maximum extensibility ("torque on" at 0.9 sec.) Uv: viscoelasticity Ur: immediate elastic recovery ("torque off" at 0.02 sec.).

    Measured: T0 (basal condition), T4 and T8 (after 4 and 8 week-treatment)

  3. Spectophotometry: change from baseline (T4 and T8 vs. T0)

    Skin colour was measured by a visible-UV-IR (λ from 300 to 900 nm) spectrophotometer which use a tungsten halogen lamp and a deuterium lamp in accordance with CIE (Commission Internationale de l'Eclarage), the main international organisation concerned with colour and colour measurement. Lamps were switched on 30 minutes before instrument use in order to join a stable emission. Measurement angle was 90° (position of the probe on the skin) and measured area was 2 mm2; used wavelength range was 380-780 nm corresponds to the visible light spectrum.

    Measured: T0 (basal condition), T4 and T8 (after 4 and 8 week-treatment)

  4. Optical colorimetry: change from baseline (T4 and T8 vs. T0)

    Measurement of skin brightness was performed by a tri-stimulus colorimeter (Chroma Meter CR-200®) equipped with three special filters to obtain R,G,B values in accordance with CIE (Commission Internationale de l'Eclarage), the main international organisation concerned with colour and colour measurement. CIE L*a*b* system (CIELAB) is the most complete colour-space specified by the CIE (1976). It describes all the colours visible to the human eye; the three coordinates of L*a*b* represent the lightness of the colour (L* = 0 yields black and L* = 100 indicates diffuse white; specular white may be higher), its position between red/magenta and green (a*, negative values indicate green while positive values indicate magenta) and its position between yellow and blue (b*, negative values indicate blue and positive values indicate yellow).

    Measured: T0 (basal condition), T4 and T8 (after 4 and 8 week-treatment)

  5. Tape stripping:

    Tape stripping was performed at each study time on the forehead on 10 selected subjects. The skin was not cleaned before tape stripping and tested area were marked with a black washable pencil. D-squame® discs (Monaderm, Monaco) with a diameter of 22mm were placed on the site of application (area without hair), applied with a constant pressure for 15 sec and then peeled off. The first two strips were discharged. Third and fourth strip were collected and stored at -20°C until following analysis listed below:

    • protein extraction and quantification
    • microscopic analysis
    • study of the expression of biological markers associated with skin ageing
    • study of ageing/oxidative stress

    Measured: T0 (basal conditions), T4 and T8 (after 4 and 8 week-treatment)

  6. Clinical evaluations: change from baseline (T4 and T8 vs. T0)

    The following clinical evaluations were performed:

    wrinkles grade (nasolabial folds and "crow's feet"): 0 = no wrinkles; 1= very weak wrinkles; 2 = weak wrinkles; 3= quite evident wrinkles; 4 = evident wrinkles; 5 = very evident wrinkles; 6 = marked wrinkles; 7 = very marked wrinkles submental ptosis, scored from 0 (absence of ptosis - very regular oval face) to 5 (very marked ptosis - very irregular oval face) according to a clinical photographic scale.

    surface microrelief: 1 = very regular; 2 = regular; 3 = irregular; 4 = very irregular skin dullness (overall face): 1= luminous skin;2 = normal skin; 3= opaque skin; 4= very opaque skin skin resistance to pinching, to traction and recovery after pinching (malar region): 0 = very important;1 = important; 2 = moderate; 3 = weak; 4 = very weak skin dryness (malar region): 0 = very hydrated skin; 1= hydrated skin; 2 = normal skin; 3= kindly dry skin; 4= dry skin ; 5= very dry skin

    Measured: T0 (basal conditions), T4 and T8 (after 4 and 8 week-treatment)

  7. Photographic documentation:

    In basal condition (T0), at T4 and at T8 the investigator took lateral pictures of each volunteer. In order to assure comparable images, the pictures were taken with standardised methods, concerning especially:

    magnification factor intensity of illumination source (photographic lamps) angle of incidence and inclination of illumination Thanks to the application "remote trigger" (Canon EOS utility software) it was possible to overlay the first photographic image (T0) with the ones taken in the following times (T4 and T8); so it was possible to have totally comparable images.

    Measured: T0 (basal condition), T4 and T8 (after 4 and 8 week-treatment)

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted3 Sep 2014 (estimated)
  2. Study startOct 2013
  3. Primary completionDec 2013
  4. Study completionDec 2013

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Single group
Masking
Double blind
Who is masked
Participant, Investigator
Enrolment
33 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT02230397
Sponsor's protocol ID
E2713
Status last verified
Jul 2014
First submitted
10 Jul 2014
Last updated
3 Sep 2014
Results posted
No
Data monitoring committee
Yes

Publications

  • Ascher B, Coleman S, Alster T, Bauer U, Burgess C, Butterwick K, Donofrio L, Engelhard P, Goldman MP, Katz P, Vleggaar D. Full scope of effect of facial lipoatrophy: a framework of disease understanding. Dermatol Surg. 2006 Aug;32(8):1058-69. doi: 10.1111/j.1524-4725.2006.32230.x.

    PubMed 16918569
  • Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 1976 May 7;72:248-54. doi: 10.1016/0003-2697(76)90527-3. No abstract available.

    PubMed 942051
  • De Jongh CM, Verberk MM, Withagen CE, Jacobs JJ, Rustemeyer T, Kezic S. Stratum corneum cytokines and skin irritation response to sodium lauryl sulfate. Contact Dermatitis. 2006 Jun;54(6):325-33. doi: 10.1111/j.0105-1873.2006.00848.x.

    PubMed 16787454
  • De Rigal J, Leveque JL In vivo measurement of the stratum corneum elasticity Bioengineering and the skin 1: 13-23, 1985

  • Elsner P, Berardesca E, Maibach H Bioengineering of the skin: Water and the stratum corneum CRC Press, Boca Raton, 1994

  • Elsner P, Barel AO, Berardesca E, Gapard B, Serup J Skin Bioengineering Techniques and Applications in Dermatology and Cosmetology Karger, 1998

  • Fernay, Voltaire The World Medical Association (1989) "World Medical Association Declaration of Helsinki", Hong-Kong.

  • Fullerton A, Fischer T, Lahti A, Wilhelm KP, Takiwaki H, Serup J. Guidelines for measurement of skin colour and erythema. A report from the Standardization Group of the European Society of Contact Dermatitis. Contact Dermatitis. 1996 Jul;35(1):1-10. doi: 10.1111/j.1600-0536.1996.tb02258.x.

    PubMed 8896947
  • Frankowsky G., Hainich R., GFMesstechnik GmbH Germany DLP-Based 3D metrology by structured light or projected fringe technology for life sciences and industrial metrology Proc. SPIE Photonics West: 1-12, 2009

  • Garcia Ortiz P, Hansen SH, Shah VP, Menne T, Benfeldt E. Impact of adult atopic dermatitis on topical drug penetration: assessment by cutaneous microdialysis and tape stripping. Acta Derm Venereol. 2009;89(1):33-8. doi: 10.2340/00015555-0562.

    PubMed 19197539
  • Glogau RG. Aesthetic and anatomic analysis of the aging skin. Semin Cutan Med Surg. 1996 Sep;15(3):134-8. doi: 10.1016/s1085-5629(96)80003-4.

    PubMed 8948530
  • Grove GL, Grove MJ, Leyden JJ. Optical profilometry: an objective method for quantification of facial wrinkles. J Am Acad Dermatol. 1989 Sep;21(3 Pt 2):631-7. doi: 10.1016/s0190-9622(89)70230-9.

    PubMed 2778127
  • Grove GL, Zerweck CR, Houser TP, Smith GE, Koski NI. A randomized and controlled comparison of gentleness of 2 medical adhesive tapes in healthy human subjects. J Wound Ostomy Continence Nurs. 2013 Jan-Feb;40(1):51-9. doi: 10.1097/WON.0b013e318276f2a4.

    PubMed 23202590
  • Hoppe U, Sauermann G, Lunderstadt R Quantitative analysis of the skin surface by means of digital signal processing J Soc Cosmet Chem 36: 105-123, 1985

  • Hof, C., Hopermann, H.: University of the Federal Armed Forces, Hamburg Comparison of Replica - and In Vivo - Measurement of the Microtopography of Human Skin

Questions about this trial

What is this clinical trial studying?

A Phase 3 study testing plantaricin a (active product) in people with Healthy, run by Derming SRL at 1 site in Italy.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 8 inclusion and 22 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 3 Sep 2014. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Italy. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Profilometry: change from baseline (T4 and T8 vs. T0) (time frame: T0 (basal conditions), T4 and T8 (after 4 and 8 week-treatment)). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT02230397, which also lists 40 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 3 Sep 2014.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in